Open Access 01-12-2014 | Study protocol
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
Published in: BMC Cardiovascular Disorders | Issue 1/2014
Login to get access